格隆汇8月18日丨九源基因(02566.HK)公布，截至2025年6月30日六个月，公司实现收入总额人民币6.388亿元，同比下降9.1%，期内溢利人民币90.2百万元，同比下降14.4%。上半年收入总额小幅下滑主要受内外部因素综合影响。医药行业政策方面，随着DRG/DIP改革持续深化，国家医保控费力度有所加强，集采外用药面临一些压力，公立医疗机构需在医保控费指标、药品性价比等方面进行再平衡；医药价格改革治理推动形成药品挂网价格规则共识，省级价格联动导致部分产品价格调整。企业自身方面，公司为加强资金回笼力度，部分产品销售模式由直销调整为商业配送；上半年公司变更名称致部分医院产品销售需重新完成市场准入工作，对公司业绩造成一定影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.